 |
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
May 15, 2013
|
19.9 KB |
|
| |
PARIS and TARRYTOWN, N.Y., May 15, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other wee...
|
|
Regeneron Announces Upcoming 2013 Investor Conference Presentations
May 8, 2013
|
9.6 KB |
|
| |
TARRYTOWN, N.Y., May 8, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
UBS Global Healthcare Conference on Monday, May 20, 2013. The presentation is scheduled for 10:00 a.m. Eastern Time.
38th Annual dbAccess Healthcare Conference on We...
|
|
Regeneron Reports First Quarter 2013 Financial and Operating Results
May 3, 2013
|
30.1 KB |
|
| |
TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the first quarter of 2013 and provided an update on development programs.
The Company reported total revenues of $440 million in the first quarter of 2013, compared to $232 million in the first qua...
|
|
Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
May 3, 2013
|
10.8 KB |
|
| |
TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi. Regeneron acquired full ...
|
|
Regeneron Announces Upcoming 2013 Investor Conference Presentations
Apr 18, 2013
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., April 18, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
Baird's 2013 Growth Stock Conference on Wednesday, May 8, 2013. The presentation is scheduled for 10:45 a.m. Eastern Time (9:45 a.m. Central Time).
Credit Suisse 2...
|
|
Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
Apr 11, 2013
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., April 11, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2013 financial and operating results on Friday, May 3, 2013, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. ...
|
|
Regeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley
Apr 4, 2013
|
10.5 KB |
|
| |
TARRYTOWN, N.Y., April 4, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company will expand the Regeneron corporate headquarters and laboratories in Westchester County and create more than 400 new high-skill jobs.
Today's announcement further cements the reputation of the Hudson Valley as an em...
|
|
Regeneron Announces Potential Additional Royalty Stream Related to EU Approval for Ilaris® (canakinumab) in Patients Suffering Acute Gouty Arthritis Attacks Who Cannot Gain Relief From Current Treatments
Mar 4, 2013
|
12.3 KB |
|
| |
TARRYTOWN, N.Y., March 4, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will receive an additional potential royalty stream now that the European Commission (EC) has approved Novartis' llaris (canakinumab, ACZ885) in the treatment of patients with acute gouty arthritis who suffer frequent attacks, and w...
|
|
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Mar 2, 2013
|
18.2 KB |
|
| |
PARIS and TARRYTOWN, N.Y., March 2, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subuni...
|
|
Regeneron Announces Upcoming 2013 Investor Conference Presentations
Feb 19, 2013
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., Feb. 19, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
Citi 2013 Global Healthcare Conference; Dyslipidemia Panel on Tuesday, February 26, 2013. The session is scheduled for 1:30 p.m. Eastern Time.
RBC Capital Markets'...
|
|
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Feb 19, 2013
|
21.1 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, Feb. 19, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated a new Phase 3 trial (named VIVID EAST-DME) to evaluate the efficacy and safety of EYLEA® (aflibercept) Injection in the treatment of Diabetic Macular Edema (DME) in Russia, China...
|
|
Regeneron Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Feb 14, 2013
|
34.3 KB |
|
| |
TARRYTOWN, N.Y., Feb. 14, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.
The Company reported total revenues of $415 million in the fourth quarter and $1.4 billion for the year ended...
|
|
Regeneron Announces Receipt of Hart-Scott-Rodino Notice
Feb 11, 2013
|
11.1 KB |
|
| |
TARRYTOWN, N.Y., Feb. 11, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it received from Sanofi a notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) that Sanofi intends to acquire Common Stock of Regeneron through open market purchases and direct purchases from sharehold...
|
|
ZALTRAP® (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Feb 5, 2013
|
60.8 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Feb. 5, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has granted marketing authorization in the European Union for ZALTRAP 25mg/ml concentrate for solution for infusion in combination with irinotecan/5-fluorou...
|
|
Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013
Jan 28, 2013
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., Jan. 28, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that it will report its fourth quarter and full year 2012 financial and operating results on Thursday, February 14, 2013, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM ES...
|
|
Regeneron Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation
Jan 4, 2013
|
11.9 KB |
|
| |
TARRYTOWN, N.Y., Jan. 4, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation to purchase up to 1 million shares, or approximately 1.06%, of the outstanding Regeneron common stock at a price of $161.25 per share. TRC's offer price represents approxima...
|
|
Regeneron Announces January 2013 Investor Conference Presentations
Dec 20, 2012
|
9.7 KB |
|
| |
TARRYTOWN, N.Y., Dec. 20, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 3, 2013. The session is scheduled for 3:15 p.m. Eastern Time.
31st Annual J. P....
|
|
EYLEA® (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Dec 6, 2012
|
18.9 KB |
|
| |
TARRYTOWN, N.Y. and BERLIN, Dec. 6, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for EYLEA (aflibercept) Injection for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO).
...
|
|
Regeneron Named Biotechnology Company of the Year
Nov 29, 2012
|
10.4 KB |
|
| |
TARRYTOWN, N.Y., Nov. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it was named "Biotechnology Company of the Year" by Scrip Intelligence at the 8th annual Scrip Awards.
The Award recognizes the biotech firm that has achieved the most in the 12 months between June 1, 2011 and May 31, 2012. In ...
|
|
Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
Nov 27, 2012
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Deutsche Bank 2012 dbAccess BioFEST on Monday, December 3, 2012. The presentation is scheduled for 1:05 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events ...
|
|
|
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds